Rondecabtagene Autoleucel

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, rondecabtagene autoleucel targets and binds to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.

**Synonyms:** - Autologous Anti-CD19/CD20 Bispecific CAR-T Cells IMPT-314 - Autologous Anti-CD19/CD20 CAR T Cells IMPT-314 - Autologous Anti-CD19/CD20 OR-gate CAR T-cells IMPT-314 - IMPT 314 - IMPT-314 - IMPT314 - RONDECABTAGENE AUTOLEUCEL